Adult Clinical Trials

Breast Cancer

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact the Breast Oncology Clinical Trials Office at 919.660.1278.

19 trials identified.

An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients
Phase: N/A
Sponsor: PI initiated
Principal Investigator: Nimmi Ramanujam
Contact: Marlee Junker
Phone: 919.660.8446
Reference Number: 00007857
View this trial at ClinicalTrials.gov

A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer
Phase: Phase II
Sponsor: External Investigator-Sponsored (External Med Ctr)
Principal Investigator: Kimberly Blackwell
Contact: Breast Oncology Clinical Trials Office
Phone: 919.660.1278
Reference Number: 00045798
View this trial at ClinicalTrials.gov

Alliance A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: BREAST ONCOLOGY CLINICAL RESEARCH TEAM
Phone: 919.660.1278
Reference Number: 00051624
View this trial at ClinicalTrials.gov

Alliance A011104 / ACRIN 6694: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: BREAST ONCOLOGY CLINICAL RESEARCH TEAM
Phone: 919.660.1278
Reference Number: 00051626
View this trial at ClinicalTrials.gov

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The METRIC Study)
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Kimberly Blackwell
Contact: BREAST ONCOLOGY CLINICAL RESEARCH TEAM
Phone: 919.660.1278
Reference Number: 00051804
View this trial at ClinicalTrials.gov

A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Phase: Phase III
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: P. Kelly Marcom
Contact: Breast Oncology Clinical Trials Office
Phone: 919.660.1278
Reference Number: 00054924
View this trial at ClinicalTrials.gov

A RANDOMIZED PHASE II STUDY OF PREOPERATIVE CISPLATIN VERSUS PACLITAXEL IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER: EVALUATING THE HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) BIOMARKER
Phase: Phase II
Sponsor: External Investigator-Sponsored (External Med Ctr)
Principal Investigator: P. Kelly Marcom
Contact: Breast Oncology Clinical Trials Office
Phone: 919.660.1278
Reference Number: 00055567
View this trial at ClinicalTrials.gov

SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: BREAST ONCOLOGY CLINICAL RESEARCH TEAM
Phone: 919.660.1278
Reference Number: 00060455
View this trial at ClinicalTrials.gov

Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients with New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer
Phase: Phase I
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Kimberly Blackwell
Contact: BREAST ONCOLOGY CLINICAL RESEARCH TEAM
Phone: 919.660.1278
Reference Number: 00061309
View this trial at ClinicalTrials.gov

NSABP B-55/BIG 6-13: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Phase: Phase III
Sponsor: Cooperative Group Initiated
Principal Investigator: P. Kelly Marcom
Contact: BREAST ONCOLOGY CLINICAL RESEARCH TEAM
Phone: 919.660.1278
Reference Number: 00061408
View this trial at ClinicalTrials.gov

Randomized Phase II trial of Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide (AC) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations DFCI 12-258
Phase: Phase II
Sponsor: External Investigator-Sponsored (External Med Ctr)
Principal Investigator: P. Kelly Marcom
Contact: BREAST ONCOLOGY CLINICAL RESEARCH TEAM
Phone: 919.660.1278
Reference Number: 00061627
View this trial at ClinicalTrials.gov

CSF Pharmacokinetics of Systemic Therapies in Patients with Advanced Cancer and Brain Metastasis
Phase: N/A
Sponsor: Internal Investigator Initiated Non-therapeutic/Non-interventional
Principal Investigator: Kimberly Blackwell
Contact: BREAST ONCOLOGY CLINICAL RESEARCH TEAM
Phone: 919.660.1278
Reference Number: 00062142

Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy
Phase: Phase I
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Kimberly Blackwell
Contact: BREAST ONCOLOGY RESEARCH CLINICAL TRIALS TEAM
Phone: 919.660.1278
Reference Number: 00062343
View this trial at ClinicalTrials.gov

LCCC 1410: Impact of Physical Activity on Biomarker of Aging and Body Composition among Breast Cancer Survivors Age 65 and Older
Phase: N/A
Sponsor: External Investigator-Sponsored (External Med Ctr)
Principal Investigator: Gretchen Kimmick
Contact: Breast Oncology Clinical Trials Office
Phone: 919.660.1278
Reference Number: 00063722
View this trial at ClinicalTrials.gov

The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with Intraductal Papilloma without Atypia or Flat Epithelial Atypia by Core Needle Biopsy
Phase: N/A
Sponsor: External Investigator-Sponsored (External Med Ctr)
Principal Investigator: Shelley Hwang
Contact: BREAST ONCOLOGY CLINICAL RESEARCH TEAM
Phone: 919.660.1278
Reference Number: 00066589
View this trial at ClinicalTrials.gov

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase: Phase II
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Kimberly Blackwell
Contact: BREAST ONCOLOGY CLINICAL RESEARCH TEAM
Phone: 919.660.1278
Reference Number: 00067720
View this trial at ClinicalTrials.gov

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer.
Phase: Phase I
Sponsor: Commercial / Industry (for-profit group) initiated
Principal Investigator: Kimberly Blackwell
Contact: Breast Oncology Clinical Research Office
Phone: 919.660.1278
Reference Number: 00068128
View this trial at ClinicalTrials.gov

Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Phase: N/A
Sponsor: Cooperative Group Initiated
Principal Investigator: Jeffrey Crawford
Contact: Breast Oncology Clinical Research Office
Phone: 919.660.1278
Reference Number: 00074506
View this trial at ClinicalTrials.gov

Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRa)-expressing, Triple Negative Breast Cancer (TNBC) with Residual Disease post Standard Neoadjuvant Chemotherapy
Phase: Phase I
Sponsor: Internal Investigator Initiated Therapeutic &/or Interventional
Principal Investigator: Kimberly Blackwell
Contact: BREAST ONCOLOGY CLINICAL RESEARCH TEAM
Phone: 919.660.1278
Reference Number: 00074621
View this trial at ClinicalTrials.gov